secwatch.observer — SEC 8-K summary
======================================

Issuer:     Instil Bio, Inc. (TIL)
CIK:        0001789769
Form:       8-K
Filed at:   2024-08-01T23:59:59+00:00
Accession:  0001789769-24-000077
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 1.01
LLM model:  deepseek-v4-flash:cloud@v2

Instil Bio licenses bispecific and CTLA-4 antibodies from ImmuneOnco in deal up to $2.15B
--------------------------------------------------------------------------------

- SynBioTx (Instil subsidiary) gains exclusive license to IMM2510 (PD-L1/VEGF) and IMM27M (CTLA-4) outside Greater China.
- ImmuneOnco receives $10M upfront, up to $50M near-term payments, plus up to $2.1B in milestones.
- Royalties on net sales outside Greater China: single-digit to low double-digit percent.
- SynBioTx can terminate for convenience on 180 days' notice; termination rights for breach or patent challenge.
- ImmuneOnco retains development and commercialization rights within China, including Hong Kong, Macau, Taiwan.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1789769/000178976924000077/0001789769-24-000077-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1789769/000178976924000077/til-20240801.htm
  HTML page:      https://secwatch.observer/filing/0001789769-24-000077

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer